The procedure with the device has been carried out as part of the FULCRUM-VT clinical study. Credit: ABRAHAM POPOCATL on Unsplash.

Adagio Medical has announced the first ultra-low temperature cryoablation (ULTC) procedure with the Adagio vCLAS catheter system in the US.

The procedure with the device has been carried out as part of the Feasibility of Ultra-Low Temperature Cryoablation for Recurring Monomorphic Ventricular Tachycardia (FULCRUM-VT) clinical study.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Dr Roderick Tung performed the procedure at Banner-University Medical Center in Phoenix, Arizona.

Tung said: “The ability of ULTC to create lesions deeper than the average thickness of ventricular myocardium exclusively from the endocardial surface in pre-clinical models is a major potential advantage.”

The trial will enrol 20 patients across four investigational sites, including Vanderbilt University Hospital in Nashville, Mount Sinai Hospital in New York, the University of California in San Francisco, and Banner-University Medical Center.

Its enrolment criteria include both ischemic and non-ischemic heart disease, an indication for ventricular ablation due to recurrent symptomatic monomorphic VTs and an implanted cardioverter defibrillator.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Additionally, the study will include patients for both de-novo and first-repeat ablation.

Adagio Medical president and CEO Olav Bergheim said: “The initiation of the FULCRUM-VT study is the first step towards bringing Adagio’s ULTC platform technology to the VT ablations market in the US.”

The CRYOCURE-VT trial in Europe and Canada, with 64 patients, to assess the safety and performance of the vCLAS catheter, has concluded enrolment and this data will be utilised to receive CE-Mark approval for the device.